Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Ultragenyx Pharmaceutical Inc. has received a consensus rating of "Moderate Buy" from twelve analysts, with eleven giving a buy rating and one a hold rating, alongside an average price target of $81.50.
• Analyst ratings have varied, with Wells Fargo decreasing their target price from $88.00 to $65.00, and Morgan Stanley reducing their target from $65.00 to $55.00.
• The company's recent earnings showed a better-than-expected performance with a reported EPS of ($1.17), surpassing analyst estimates, and a revenue increase of 13.2% year-over-year.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $81.50.

Several equities research analysts recently issued reports on RARE shares. Cantor Fitzgerald restated an "overweight" rating and issued a $105.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, September 5th. Morgan Stanley decreased their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Wells Fargo & Company decreased their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Guggenheim reiterated a "buy" rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Finally, Canaccord Genuity Group decreased their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday, August 8th.

Ultragenyx Pharmaceutical Trading Down 3.4%

RARE stock traded down $0.98 on Tuesday, hitting $28.13. The company had a trading volume of 3,627,110 shares, compared to its average volume of 1,390,204. Ultragenyx Pharmaceutical has a 12-month low of $25.81 and a 12-month high of $59.50. The stock's 50-day simple moving average is $28.97 and its 200 day simple moving average is $34.01. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of -5.09 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. During the same quarter last year, the company posted ($1.52) earnings per share. The firm's quarterly revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of the firm's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the sale, the executive vice president directly owned 73,271 shares in the company, valued at $2,283,857.07. This trade represents a 3.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 5.50% of the stock is owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of RARE. Norges Bank bought a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $35,765,000. Adage Capital Partners GP L.L.C. raised its position in shares of Ultragenyx Pharmaceutical by 81.6% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock valued at $77,815,000 after purchasing an additional 965,919 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Ultragenyx Pharmaceutical by 439.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company's stock valued at $42,314,000 after purchasing an additional 947,865 shares during the period. Vestal Point Capital LP raised its position in shares of Ultragenyx Pharmaceutical by 100.0% during the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock valued at $63,105,000 after purchasing an additional 750,000 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Ultragenyx Pharmaceutical by 28.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock valued at $116,559,000 after purchasing an additional 706,519 shares during the period. 97.67% of the stock is currently owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.